Economic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer;Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule

PharmacoEconomics - Italian Research Articles

Volumn 9, Issue 2, 2007, Pages 113-124

  Capri, Stefano ^a   Morabito, A ^b   Carillio, G ^c   Grossi, F ^d   Longo, R ^e   Cerea, G ^f   Rossetti, F ^g  

^a CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Humanitas Centro Catanese di Oncologia   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e Divisione di Oncologia Medica   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g ROCHE MILANO RICERCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; IFOSFAMIDE; NAVELBINE; PEMETREXED;

ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; HOSPITAL COST; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; SENSITIVITY ANALYSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

EID: 34748910727     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320705     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
2. Bonadonna G, Robustelli della Cuna G, Valagussa P. Medicina oncologica. VII ed. Milano: Masson, 2003
3. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-84
4. De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology. VI ed. Philadelphia: Lippincott Williams & Wilkins, 2000
5. Molinier L, Combescure C, Chouaid C, et al. Cost of lung cancer. A methodological review. Pharmacoeconomics 2006; 24: 651-9
6. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
7. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Economics 2001; 10: 179-84
8. Fossella FV, DeVore R, Kerr R, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-62
9. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with Non-Small-Cell Lung Cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103
10. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with Non-Small-Cell Lung Cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97
11. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated Non-Small-Cell Lung Cancer. N Engl J Med 2005; 353: 123-32
12. Cagnoni P, Christy-Bittel J, McCarthy S, Clark G. Survival benefit from erlotinib (Tarceva) in NSCLC patients with good prognostic factors. Poster presented at 31st ESMO Congress, Istanbul, September-October 2006
13. Schivazappa C, Baldini E, Cortesi E, et al. Analisi dei costi di trattamento dell'osteolisi tumorale con acido zoledronico e pamidronato per via endovenosa: uno studio tempi & metodi. Recenti Prog Med 2007; 98: 12-5
14. Ministero della Salute. Nomenclatore Tariffario di Assistenza Specialistica Ambulatoriale, DM 22 Luglio 1996
15. Agenzia per i Servizi Sanitari Regionali. Ricoveri, personale e spesa delle aziende ospedaliere 2003
16. Ministero dell'Economia e delle Finanze. Relazione generale sulla situazione economica del Paese, 2005
17. DGR n. 1843 - Pubblicata sul BUR Campania n. 1 del 2 gennaio 2006: "Equilibrio economico delle ASL, delle AO, delle AO universitarie e della Fondazione Pascale. Disposizioni per la programmazione 2006-2008"
18. Rapporto OASI 2006. Centro di Ricerche sulla Gestione dell' Assistenza Sanitaria e Sociale dell'Università Bocconi (CERGAS) 19. Tariffa Unica Convenzionale per le Prestazioni di Assistenza Ospedaliera per Acuti